Uveitic Macular Edema: Assessing and Treating a Complex Condition
This program is intended for ASRS attendees only.
Activity Chair
Pauline T. Merrill, MD, FASRS
Associate Professor
Rush University
Chicago, IL
Faculty
Christopher R. Henry, MD
Partner Physician
Retina Consultants of Texas
Clinical Associate Professor of Ophthalmology
McGovern Medical School
University of Texas Health Science Center at Houston
Houston, TX
Ashvini K. Reddy, MD
Medical Director
Athena Eye Institute
San Antonio, TX
Overview
Development of uveitic macular edema (UME) in patients with uveitis is associated with considerable clinical and economic burden, and it is the most common cause of vision loss, regardless of the anatomical type of uveitis present. The lack of treatment guidelines for the management of UME, along with no FDA-approved therapies, has further added to the challenge of care for these patients. Systemic, topical, or intravitreal corticosteroids have been utilized as first-line therapies, depending on the etiology and severity. In patients who are non-responsive to steroids, immunosuppressants, biological therapies, and vitreoretinal surgery have been used. The FDA recently approved the first therapy for the treatment of UME providing an innovative treatment option for these patients. In this continuing medical education activity, experts in the field discuss the complex etiologies of UME, evaluate modalities that effectively aid in the differential diagnosis of UME, and review new evidence regarding the safety and efficacy of conventional, new, and emerging treatment options for patients with UME.
Agenda
6:00 PM
Registration and Dinner
6:30 PM
Introduction and Pretest
Pauline T. Merrill, MD, FASRS
6:35 PM
Uveitic Macular Edema: Assessing its Diverse Etiologies
Pauline T. Merrill, MD, FASRS
6:55 PM
Differentiating Uveitic Macular Edema
Ashvini K. Reddy, MD
7:15 PM
Uveitic Macular Edema Treatment: Lessons Learned
Christopher R. Henry, MD
7:45 PM
Posttest and Question & Answer
8:00 PM
Conclusion
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Recognize UME as a complication of a heterogeneous group of diseases with complex etiologies.
Review modalities that effectively aid in the differential diagnosis of UME.
Assess new evidence regarding the safety and efficacy of conventional, new, and emerging treatment options for the treatment of UME.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with UME.
This continuing medical education activity is provided by Vindico Medical Education.
This activity is supported by an educational grant from Bausch + Lomb.
This program is not affiliated with ASRS.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
This program is intended for ASRS attendees only.
Activity Chair
Pauline T. Merrill, MD, FASRS
Associate Professor
Rush University
Chicago, IL
Faculty
Christopher R. Henry, MD
Partner Physician
Retina Consultants of Texas
Clinical Associate Professor of Ophthalmology
McGovern Medical School
University of Texas Health Science Center at Houston
Houston, TX
Ashvini K. Reddy, MD
Medical Director
Athena Eye Institute
San Antonio, TX
Overview
Development of uveitic macular edema (UME) in patients with uveitis is associated with considerable clinical and economic burden, and it is the most common cause of vision loss, regardless of the anatomical type of uveitis present. The lack of treatment guidelines for the management of UME, along with no FDA-approved therapies, has further added to the challenge of care for these patients. Systemic, topical, or intravitreal corticosteroids have been utilized as first-line therapies, depending on the etiology and severity. In patients who are non-responsive to steroids, immunosuppressants, biological therapies, and vitreoretinal surgery have been used. The FDA recently approved the first therapy for the treatment of UME providing an innovative treatment option for these patients. In this continuing medical education activity, experts in the field discuss the complex etiologies of UME, evaluate modalities that effectively aid in the differential diagnosis of UME, and review new evidence regarding the safety and efficacy of conventional, new, and emerging treatment options for patients with UME.
Agenda
6:00 PM
Registration and Dinner
6:30 PM
Introduction and Pretest
Pauline T. Merrill, MD, FASRS
6:35 PM
Uveitic Macular Edema: Assessing its Diverse Etiologies
Pauline T. Merrill, MD, FASRS
6:55 PM
Differentiating Uveitic Macular Edema
Ashvini K. Reddy, MD
7:15 PM
Uveitic Macular Edema Treatment: Lessons Learned
Christopher R. Henry, MD
7:45 PM
Posttest and Question & Answer
8:00 PM
Conclusion
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Recognize UME as a complication of a heterogeneous group of diseases with complex etiologies.
Review modalities that effectively aid in the differential diagnosis of UME.
Assess new evidence regarding the safety and efficacy of conventional, new, and emerging treatment options for the treatment of UME.
Target Audience
The intended audience for this activity is retina specialists and other health care professionals involved in the management of patients with UME.
This continuing medical education activity is provided by Vindico Medical Education.
This activity is supported by an educational grant from Bausch + Lomb.
This program is not affiliated with ASRS.
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Vindico Medical Education designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn Continuing Certification credits equivalent to the amount of CME credits claimed for the activity.
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.